Nicole S. White - Mar 29, 2024 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)

Role
Chief Manufacturing Officer
Signature
/s/ John O. Gunderson, as Attorney-in-Fact
Stock symbol
ASMB
Transactions as of
Mar 29, 2024
Transactions value $
-$2,575
Form type
4
Date filed
4/2/2024, 04:15 PM
Previous filing
Nov 21, 2023
Next filing
May 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ASMB Common Stock Sale -$2.58K -197 -1.77% $13.07 10.9K Apr 1, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ASMB Stock Option (right to buy) Award $0 +17.5K $0.00 17.5K Mar 29, 2024 Common Stock 17.5K $13.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.30, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
F3 Reflects equitable adjustment of the number of shares beneficially owned by the reporting person resulting from a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2023, which is exempt from reporting pursuant to Rule 16a-9.
F4 Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2025; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2028.